A transposon screen identifies enhancement of NF-κB pathway as a mechanism of resistance to eribulin.
Xiaozhong TengTetsu HayashidaTakeshi MurataAiko NagayamaTomoko SekiMaiko TakahashiYuko KitagawaPublished in: Breast cancer (Tokyo, Japan) (2021)
These results consistently illustrated that TAB2-NF-κB pathway may increases resistance to eribulin in breast cancer models. Moreover, these results support the use of a combination strategy of eribulin with NF-κB inhibitors, and provide evidence that transposon mutagenesis screens are capable of identifying drug-resistant genes.
Keyphrases
- drug resistant
- signaling pathway
- metastatic breast cancer
- lps induced
- genome wide
- multidrug resistant
- pi k akt
- nuclear factor
- acinetobacter baumannii
- phase ii
- high throughput
- oxidative stress
- inflammatory response
- dna methylation
- clinical trial
- crispr cas
- cell proliferation
- young adults
- toll like receptor
- single cell
- study protocol
- transcription factor
- genome wide identification
- open label